Skip to main content
PFE
NYSE Life Sciences

Pfizer 10-Q Details $4.3B Impairments, New $2.5B Savings Push Behind Raised Guidance

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Neutral
Importance info
8
Price
$30.659
Mkt Cap
$174.809B
52W Low
$23.62
52W High
$31.04
52W Position info
30% above low
Off High info
1.2% below high
Rel. Volume info
1.5× avg
Market data snapshot near publication time

PFE sits 30% above its 52-week low of $23.62.

Summary

Pfizer's Q3 10-Q backs up its raised guidance with full financials: nine-month net income down 40% to $5.68 billion on $4.3 billion of impairments, offset by $8.8 billion of operating cash flow and a new $2.5 billion cost-savings push.


Key Events · Earnings and Guidance · PFE

  • Q3 Revenue Flat, Non-COVID Up 7%

    Third-quarter 2026 revenues were $16,583 million versus $16,654 million a year earlier; excluding Comirnaty and Paxlovid, revenue grew 7% operationally.

  • $4.3B Impairments Hit Nine-Month Earnings

    Nine-month net income attributable to Pfizer fell to $5,681 million from $9,419 million, driven by $4,325 million of impairments — $3.8 billion on sigvotatug vedotin IPR&D and $525 million on Oxbryta developed technology rights.

  • New $2.5B Cost-Savings Round Announced

    Pfizer added $1.0 billion of net savings to its Realigning Our Cost Base Program and launched a next manufacturing phase targeting ~$1.5 billion of savings, with one-time costs of ~$4.0 billion through 2029 (about 60% non-cash).

  • Operating Cash Flow Rises to $8.8B

    Nine-month operating cash flow was $8,825 million versus $6,356 million a year earlier, helped by the $1.875 billion ViiV sale proceeds and lower upfront licensing payments ($650 million to Innovent versus $1.35 billion to 3SBio).


Analysis · PFE · Life Sciences

This filing is the full financial backup to Pfizer's same-day Q3 earnings release, and it carries the parts the press release only summarized. Nine-month net income fell 40% to $5.68 billion, dragged by $4.325 billion of intangible write-downs — $3.8 billion on the failed sigvotatug vedotin lung-cancer program and $525 million on Oxbryta after the FDA confirmed no path back to market. Against that, Pfizer announced a fresh round of cost cuts in Q3: $1.0 billion of additional net savings in the Realigning Our Cost Base Program and a next phase of manufacturing optimization worth about $1.5 billion, at a one-time cost of roughly $4.0 billion (about 60% non-cash). Cash generation is the offset — operating cash flow rose to $8.8 billion from $6.4 billion — and the balance sheet still carries $60 billion of long-term debt against $14.3 billion of cash and short-term investments. The write-downs explain why reported EPS ($0.56) sits well below adjusted EPS ($0.87), which is the number behind the raised $2.95-$3.05 guidance.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, PFE was trading at $30.66 on NYSE in the Life Sciences sector, with a market capitalization of approximately $174.8B. The 52-week trading range was $23.62 to $31.04. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PFE - Latest Insights

PFE
Nov 16, 2026, 6:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $29.12
Real-time Price: $28.30 info
Change: -$0.820 (-3%) info
Market Cap: $162.275B info
PFE
Nov 13, 2026, 3:19 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $28.85
Real-time Price: $28.30 info
Change: -$0.5525 (-2%) info
Market Cap: $162.275B info
PFE
Nov 11, 2026, 4:30 PM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $29.45
Real-time Price: $28.30 info
Change: -$1.15 (-4%) info
Market Cap: $162.275B info
PFE
Nov 03, 2026, 8:07 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $30.62
Real-time Price: $28.30 info
Change: -$2.32 (-8%) info
Market Cap: $162.275B info
PFE
Nov 03, 2026, 6:55 AM EST
Source: Reuters
Importance Score:
8
Price at Filing: $30.73
Real-time Price: $28.30 info
Change: -$2.43 (-8%) info
Market Cap: $162.275B info